Collaborations between universities and firms are of growing interest to scholars and practitioners alike, many of whom see these relationships as key to knowledge diffusion. While the literature on university-firm collaborations has made a number of contributions, however, it has not engaged in...

This study deals with the organization of industry-science collaboration in the case of knowledge transfer for radical innovation. Based on a contingency notion, the relation between research and development (R&D) projects’ properties and the way of collaboration is explored. By means of...

In 1996, the chemical firm Monsanto bought a plant breeder that had developed a new corn hybrid, which could withstand Monsanto’s powerful herbicide Roundup. Due to the pre-existing structure of the US plant-breeding industry, this acquisition and Monsanto’s acquisition of five other corn...

These are neither the best of times nor the worst of times for the pharmaceutical industry, or for global public health. Media reports regarding recent legal developments would suggest that the originator pharmaceutical industry is facing a new and dangerous threat to its long-term welfare,...

This paper reports on the findings of interviews conducted with Hungarian firms on their overall business and innovation strategies and innovation activities to pursue three interconnected aims: a) better understand firm behaviour by analysing qualitative features of innovation processes...

Professor Sichelman’s article on “Purging Patent Law of Private Law Remedies” offers a welcome and useful perspective on the reform of patent remedies. In this comment I critique some of his assumptions regarding the “private” nature of patent and other remedies, then turn to...

Is antitrust law up to the task of addressing the "New Economy"? That is the question many have asked in recent years. And that is one of the key questions addressed by the Antitrust Modernization Commission ("AMC"), a commission that Congress established in 2002 "to examine whether the need...

One of the most heated discussions in economics in recent years has concerned the relationship between market structure and innovation. After a half-century of debate and innumerable studies, the consensus is that there is no clear answer to the question. On a concrete level, the uncertainty...

Drug recalls, contamination events, and shortages are on the rise, but drug companies still rely on decades-old manufacturing plants and processes. Contrary to widespread perceptions, drug manufacturing is typically expensive, inefficient, and non-innovative. Drug companies spend much more on...

Scholars argue that the presence of persistent first-mover advantages obviates the need for relatively long-lived patents as incentives for innovations. What then is the impact of the strengthening of patent protection, particularly in developing economies, on non-patent-based first-mover...